Machina Capital S.A.S. Purchases Shares of 22,163 Hologic, Inc. (NASDAQ:HOLX)

Machina Capital S.A.S. purchased a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 22,163 shares of the medical equipment provider's stock, valued at approximately $1,369,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HOLX. Beverly Hills Private Wealth LLC raised its stake in Hologic by 3.6% during the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock worth $320,000 after buying an additional 180 shares during the period. Allworth Financial LP raised its position in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares during the period. Dark Forest Capital Management LP lifted its holdings in shares of Hologic by 7.9% in the 4th quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock worth $220,000 after purchasing an additional 223 shares in the last quarter. Baker Avenue Asset Management LP grew its position in Hologic by 0.5% in the 4th quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock valued at $3,031,000 after purchasing an additional 225 shares during the period. Finally, Integrated Advisors Network LLC grew its position in Hologic by 5.4% in the 1st quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock valued at $346,000 after purchasing an additional 289 shares during the period. 94.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

HOLX has been the subject of a number of analyst reports. Royal Bank Of Canada reduced their price objective on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Mizuho lifted their price target on Hologic from $65.00 to $70.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Evercore ISI raised their target price on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Finally, Morgan Stanley lowered their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Hologic currently has an average rating of "Hold" and an average target price of $77.33.

Hologic Stock Performance

Hologic stock traded up $0.40 during trading on Friday, hitting $66.50. The stock had a trading volume of 1,116,538 shares, compared to its average volume of 1,795,352. The stock's 50 day moving average is $63.33 and its two-hundred day moving average is $63.00. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67. The stock has a market cap of $14.82 billion, a price-to-earnings ratio of 28.06, a price-to-earnings-growth ratio of 2.42 and a beta of 0.55. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. During the same quarter in the prior year, the firm earned $1.03 EPS. The business's revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Activity at Hologic

In other Hologic news, Director Martin D. Madaus acquired 5,445 shares of the business's stock in a transaction that occurred on Wednesday, May 7th. The stock was bought at an average cost of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director owned 5,445 shares in the company, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.88% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.